title: Circadian blood pressure variation in patients with renovascular hypertension or primary aldosteronism.
abstract: Circadian blood pressure (BP) variation were studied in patients with renovascular hypertension (RVH) and primary aldosteronism (PA). Ambulatory BP (ABP) was monitored every 5 min for 24 hrs in a ward setting in 23 patients with PA and 17 patients with RVH (13 patients with unilateral renal arterial stenosis and 4 with bilateral stenosis). In patients with RVH, ABP was monitored before and after treatment with a converting enzyme inhibitor or percutaneous transluminal angioplasty. Plasma renin activity (PRA) was high before percutaneous transluminal angioplasty in almost all patients with RVH and low in those with PA. Ordinary circadian BP variation, i.e. nocturnal fall and diurnal rise in BP, was confirmed in the patients with unilateral or bilateral renal artery stenosis. Percutaneous transluminal angioplasty successfully normalized both BP and PRA in those with RVH. Normal circadian BP variation was observed in those with RVH before the treatment with a converting enzyme inhibitor or percutaneous transluminal angioplasty as well as during treatment with the former and after treatment with the latter. Circadian BP variation in the patients with RVH was affected by the pathogenesis of renal artery stenosis alone, i.e, fibromuscular hyperplasia and atherosclerosis; with fibromuscular hyperplasia normal circadian BP variation was observed, while with atherosclerosis, nocturnal BP fall was restricted or eliminated. Circadian BP variation in those with PA before and after excision of adrenal adenoma was essentially similar to that in normal subjects and essential hypertensive patients. From these it seems that in patients with RVH or PA, circadian BP variation is not affected by hypertension per se or by pathogenesis of hypertension.
authors.affiliation: Department of Medicine, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Imai
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: S
authors.initials: S
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Munakata
authors.forename: N
authors.initials: N
authors.lastname: Minami
authors.forename: H
authors.initials: H
authors.lastname: Sakuma
authors.forename: J
authors.initials: J
authors.lastname: Hashimoto
authors.forename: T
authors.initials: T
authors.lastname: Yabe
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: M
authors.initials: M
authors.lastname: Sakuma
mesh_terms: D000236:Adenoma / Q000150:complications / Q000601:surgery; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000601:surgery; D000328:Adult; D000800:Angioplasty, Balloon; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001794:Blood Pressure; D002940:Circadian Rhythm; D006339:Heart Rate; D006801:Humans; D006929:Hyperaldosteronism / Q000209:etiology / Q000503:physiopathology*; D006973:Hypertension / Q000503:physiopathology; D006978:Hypertension, Renovascular / Q000188:drug therapy / Q000503:physiopathology*; D012016:Reference Values; D012078:Renal Artery Obstruction / Q000628:therapy
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors